Treating psoriasis with adalimumab

Figures & data

Figure 1 Percentage of patients achieving 75% improvement in Psoriasis Area and Severity Index response at week 12 in the phase II and phase III trials. Because the phase II trial did not have week 16 data (the primary endpoint for the phase III trials), we compared the week 12 PASI 75 for all three clinical trials.

Figure 2 Clinical and histological response of subject in phase II study of adalimumab after 12 weeks. Clinical photos target lesion at day 0 (A) and day 84 (B) and representative histological specimens at day 0 (C) and day 84 (D).

Table 1 Adverse events in adalimumab psoriasis trials

Common adverse events in phase III psoriasis trial of adalimumab (Menter et al 2007)
Adverse event	% reported
Upper respiratory infection	7.2%
Nasopharyngitis	5.3%
Headache	4.9%
Injection site reactions	3.1%
Serious adverse events in RA open label adalimumab trial (Burmester et al 2007)
Adverse event	% reported
Serious infections	1.7%
Malignanciesa	0.65%
Congestive heart failurea	0.3%
Demyelinating diseasea	0.06%
Systemic lupus erythematosus	0.03%

a Inclusive of adalimumab monotherapy and adalimumab plus disease-modifying antirheumatic drugs.

MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJ Am Acad Derm2007In press

 Google Scholar

BurmesterGRMarietteXMontecuccoCAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialAnn Rheum Dis200766732917329305

 PubMed Web of Science ®Google Scholar